Casi pharmaceuti­­­cals announces partner juventas completion of series c financing of $63 million (rmb410 million) for acceleration of cnct19 pivotal trials and commercialization

Rockville, md. and beijing, oct. 25, 2021 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that juventas cell therapy ltd.
CASI Ratings Summary
CASI Quant Ranking